Aurobindo Pharma's subsidiary, CuraTeQ Biologics, secured European Commission approval for its trastuzumab biosimilar, ...

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...

EAU guidelines offer updated guidance on diagnosis, treatment, & follow-up of patients with metastatic & muscle-invasive ...

Puma Biotechnology reported inducement restricted stock units awarded to new hires in June 2025, as required by Nasdaq ...

The EC granted conditional approval based on activity seen in a subset of IHC 3+ HER2-positive advanced biliary tract cancer patients in a Phase II trial.

US biotech Jazz Pharmaceuticals yesterday announced that the European Commission (EC) has granted conditional marketing ...

China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, ...

Aurobindo Pharma’s Dazublys, a trastuzumab biosimilar for HER2-positive cancers, gains EU approval, enhancing access to ...

Recurrence means that cancer has come back after initial treatment and a period during which it could not be detected. Even ...

Topline data were announced from a phase 3 trial evaluating bemarituzumab plus chemotherapy in individuals with gastric or gastroesophageal junction cancer with FGFR2b overexpression.

CuraTeQ Biologics, a wholly owned subsidiary of the company dedicated to oncology and immunology segments, has received authorisation from the European authorities.

CuraTeQ Biologics, a unit of Aurobindo Pharma, has received EU approval to market Dazublys, its trastuzumab biosimilar for ...